Guillain Barre Syndrome (GBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Guillain Barre Syndrome (GBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Guillain Barre Syndrome market. The report identifies the key trends shaping and driving the global Guillain Barre Syndrome market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Guillain Barre Syndrome sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by GlobalData’s team of industry experts.

GlobalData’s analysis revealed that the global Guillain Barre Syndrome market was worth $370m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 5.1% over the next seven years, to reach $520m by 2017. This is primarily attributed to the predicted increase in the prevalence of the disease.

Scope

The report provides information on the key drivers and challenges of the Guillain Barre Syndrome market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Guillain Barre Syndrome market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets.
• Analysis of the current and future competition in the seven key countries Guillain Barre Syndrome market. Key market players covered are Baxter Biotherapeutics, Grifols Biologics Inc. and CSL Behring.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Guillain Barre Syndrome therapeutics market.
• Analysis of key recent licensing and partnership agreements in Guillain Barre Syndrome market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Guillain Barre Syndrome market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Guillain Barre Syndrome market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Guillain Barre Syndrome market landscape? – Identify, understand and capitalize.

Table of contents

1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4

2 Guillain Barre Syndrome Therapeutics - Introduction 5
2.1 Overview 5
2.2 Etiology and Pathophysiology 5
2.3 Epidemiology 6
2.4 Symptoms 6
2.5 Diagnosis 6
2.6 Treatment and Management Pattern 7
2.7 GlobalData Report Guidance 7

3 Guillain Barre Syndrome Therapeutics - Market Characterization 8
3.1 GBS Therapeutics Market Size (2005 - 2010) - Global 8
3.2 GBS Therapeutics Market Forecast (2010 - 2017) - Global 9
3.3 GBS Therapeutics Market Size (2005 - 2010) - The US 10
3.4 GBS Therapeutics Market Forecast (2010 - 2017) - The US 11
3.5 GBS Therapeutics Market (2005 - 2010) - France 12
3.6 GBS Therapeutics Market Forecast (2010 - 2017) - France 13
3.7 GBS Therapeutics Market (2005 - 2010) - Germany 14
3.8 GBS Therapeutics Market Forecast (2010 - 2017) - Germany 15
3.9 GBS Therapeutics Market (2005 - 2010) - Italy 16
3.10 GBS Therapeutics Market Forecast (2010 - 2017) - Italy 17
3.11 GBS Therapeutics Market (2005 - 2010) - Spain 18
3.12 GBS Therapeutics Market Forecast (2010 - 2017) - Spain 19
3.13 GBS Therapeutics Market (2005 - 2010) - The UK 20
3.14 GBS Therapeutics Market Forecast (2010 - 2017) - The UK 21
3.15 GBS Therapeutics Market (2005 - 2010) - Japan 22
3.16 GBS Therapeutics Market Forecast (2010 - 2017) - Japan 23
3.17 Drivers and Barriers for the Guillain Barre Syndrome Therapeutics Market 24
3.17.1 Drivers for the GBS Therapeutics Market 24
3.17.2 Barriers for the GBS Therapeutics Market 24
3.18 Opportunity and Unmet Need Analysis 25
3.19 Key Takeaway 25

4 Guillain Barre Syndrome Therapeutics - Competitive Assessment 26
4.1 Overview 26
4.1.1 Strategic Competitor Assessment 26
4.2 Product Profile for the Major Marketed Products in the GBS Therapeutics Market 27
4.2.1 Kiovig (Gammagard Liquid + rHuPH20) 27
4.3 Key Takeaway 27

5 Guillain Barre Syndrome Therapeutics - Pipeline Assessment 28
5.1 Overview 28

6 Guillain Barre Syndrome Therapeutics - Clinical Trials Mapping 29
6.1 Overview 29

7 Guillain Barre Syndrome Therapeutics - Stategic Assessment 30
7.1 Key Events Impacting on the Future Market 30
7.2 Guillain Barre Syndrome Therapeutics - Implications for Future Market Competition 30

8 Guillain Barre Syndrome Therapeutics - Future Players 32
8.1 Introduction 32
8.2 Company Profiles 32
8.2.1 Baxter Biotherapeutics 32
8.2.2 Grifols Biologicals Inc 33
8.2.3 CSL Behring 33

9 Guillain Barre Syndrome Therapeutics - Appendix 34
9.1 Market Definitions 34
9.2 Abbreviations 34
9.3 Methodology 34
9.3.1 Coverage 34
9.3.2 Secondary Research 35
9.3.3 Forecasting 35
9.3.4 Primary Research 37
9.3.5 Expert Panels Validation 38
9.4 Contact Us 38
9.5 Disclaimer 38
9.6 Bibliography 39

List of Tables

Table 1: GBS Therapeutics Market, Global, Revenue ($m), 2005 - 2010 8
Table 2: GBS Therapeutics Market, Global, Forecast ($m), 2010 - 2017 9
Table 3: GBS Therapeutics Market, The US, Revenue ($m), 2005 - 2010 10
Table 4: GBS Therapeutics Market, The US, Forecast ($m), 2010 - 2017 11
Table 5: GBS Therapeutics Market, France, Revenue ($m), 2005 - 2010 12
Table 6: GBS Therapeutics Market, France, Forecast ($m), 2010 - 2017 13
Table 7: GBS Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 14
Table 8: GBS Therapeutics Market, Germany, Forecast ($m), 2010 - 2017 15
Table 9: GBS Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 16
Table 10: GBS Therapeutics Market, Italy, Forecast ($m), 2010 - 2017 17
Table 11: GBS Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 18
Table 12: GBS Therapeutics Market, Spain, Forecast ($m), 2010 - 2017 19
Table 13: GBS Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 20
Table 14: GBS Therapeutics Market, The UK, Forecast ($m), 2010 - 2017 21
Table 15: GBS Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 22
Table 16: GBS Therapeutics Market, Japan, Forecast ($m), 2010 - 2017 23
Table 17: Strategic Competitor Assessment of the Major Marketed Products for GBS, 2011 26

List of Figures

Figure 1: GBS Classification 5
Figure 2: Structure of Neuron 6
Figure 3: GBS Therapeutics Market, Global, Revenue($m), 2005 - 2010 8
Figure 4: GBS Therapeutics Market, Global, Forecast ($m), 2010 - 2017 9
Figure 5: GBS Therapeutics Market, The US, Revenue ($m), 2005 - 2010 10
Figure 6: GBS Therapeutics Market, The US, Forecast ($m), 2010 - 2017 11
Figure 7: GBS Therapeutics Market, France, Revenue ($m), 2005 - 2010 12
Figure 8: GBS Therapeutics Market, France, Forecast ($m), 2010 - 2017 13
Figure 9: GBS Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 14
Figure 10: GBS Therapeutics Market, Germany, Forecast ($m), 2010 - 2017 15
Figure 11: GBS Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 16
Figure 12: GBS Therapeutics Market, Italy, Forecast ($m), 2010 - 2017 17
Figure 13: GBS Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 18
Figure 14: GBS Therapeutics Market, Spain, Forecast ($m), 2010 - 2017 19
Figure 15: GBS Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 20
Figure 16: GBS Therapeutics Market, The UK, Forecast ($m), 2010 - 2017 21
Figure 17: GBS Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 22
Figure 18: GBS Therapeutics Market, Japan, Forecast ($m), 2010 - 2017 23
Figure 19: Opportunity and Unmet Need in the Guillain Barre Syndrome Therapeutics Market, 2010 25
Figure 20: Drivers and Barriers of the GBS Therapeutics Market 30
Figure 21: Implications for Future Market Competition in the GBS Therapeutics Market, 2011 30